<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004482</url>
  </required_header>
  <id_info>
    <org_study_id>199/14209</org_study_id>
    <secondary_id>MAYOC-1479901</secondary_id>
    <secondary_id>MAYOC-1479900</secondary_id>
    <nct_id>NCT00004482</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Assess the effect of immunosuppression with muromonab-CD3, cyclosporine,
      methylprednisolone, and prednisone versus standard care in terms of death, heart
      transplantation, or left ventricular assistive device placement in patients with giant cell
      myocarditis.

      II. Compare left ventricular ejection fraction prior to and after 4 weeks of treatment in
      these arms.

      III. Compare the degree of myocardial inflammatory infiltrate prior to and after 4 weeks of
      treatment in these arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      This is a randomized, open label, multicenter study.

      Patients are randomized to receive standard care with immunosuppression (arm I) or standard
      care with or without immunosuppression (no muromonab-CD3 or cyclosporine)(arm II).

      Arm I: Patients receive methylprednisolone IV once daily for 3 days and muromonab-CD3 IV once
      daily for 10 days. Oral cyclosporine is administered twice daily and oral prednisone is
      administered once daily for 1 year.

      Arm II: Patients receive standard care with or without immunosuppression (no muromonab-CD3 or
      cyclosporine).

      Patients are followed for one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Myocarditis</condition>
  <condition>Giant Cell Myocarditis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Muromonab-CD3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Idiopathic giant cell myocarditis confirmed by endomyocardial biopsy

        Heart failure and/or arrhythmia of less than 3 months duration

        --Patient Characteristics--

        Hepatic: AST/ALT no greater than 3 times upper limit of normal

        Renal: Creatinine no greater than 2.5 mg/dL

        Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use
        effective contraception; No clinical evidence of sepsis or active infection (e.g.
        meningitis, osteomyelitis, etc.); No contraindication to immunosuppression; No allergy to
        cyclosporine or muromonab-CD3; No other severe concurrent diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie T. Cooper, Jr.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>giant cell myocarditis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

